pharmaphorum21 小时
Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO
There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu. The US Patent and Trademark ...
pharmaphorum21 小时
AZ, Daiichi eye December verdict for TROP2 ADC
The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC) alliance, with a ...